KR20190009804A - 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물 - Google Patents

비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물 Download PDF

Info

Publication number
KR20190009804A
KR20190009804A KR1020187037187A KR20187037187A KR20190009804A KR 20190009804 A KR20190009804 A KR 20190009804A KR 1020187037187 A KR1020187037187 A KR 1020187037187A KR 20187037187 A KR20187037187 A KR 20187037187A KR 20190009804 A KR20190009804 A KR 20190009804A
Authority
KR
South Korea
Prior art keywords
bvd
braf
cells
inhibitor
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187037187A
Other languages
English (en)
Korean (ko)
Inventor
사우라브 사하
딘 웰쉬
개리 데크레스센조
제프리 제임스 로익스
Original Assignee
바이오메드 밸리 디스커버리즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오메드 밸리 디스커버리즈, 인코포레이티드 filed Critical 바이오메드 밸리 디스커버리즈, 인코포레이티드
Priority to KR1020237004648A priority Critical patent/KR20230025941A/ko
Publication of KR20190009804A publication Critical patent/KR20190009804A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
KR1020187037187A 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물 Ceased KR20190009804A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237004648A KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361919551P 2013-12-20 2013-12-20
US15/161,137 US20160317519A1 (en) 2013-12-20 2016-05-20 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
US15/161,137 2016-05-20
PCT/US2017/033843 WO2017201532A1 (en) 2013-12-20 2017-05-22 Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237004648A Division KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Publications (1)

Publication Number Publication Date
KR20190009804A true KR20190009804A (ko) 2019-01-29

Family

ID=53403903

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187037187A Ceased KR20190009804A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
KR1020237004648A Ceased KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020237004648A Ceased KR20230025941A (ko) 2013-12-20 2017-05-22 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물

Country Status (16)

Country Link
US (5) US20160317519A1 (https=)
EP (2) EP3458056B1 (https=)
JP (4) JP7427212B2 (https=)
KR (2) KR20190009804A (https=)
CN (2) CN109475541A (https=)
AU (3) AU2017267804B2 (https=)
BR (1) BR112018073786A2 (https=)
CA (1) CA3024703A1 (https=)
CL (1) CL2018003282A1 (https=)
ES (1) ES3056393T3 (https=)
IL (2) IL294056A (https=)
MX (2) MX392121B (https=)
RU (1) RU2018145048A (https=)
SG (1) SG11201810287RA (https=)
WO (2) WO2015095842A2 (https=)
ZA (2) ZA201808480B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
TWI674262B (zh) 2011-01-10 2019-10-11 美商英菲尼提製藥股份有限公司 製備異喹啉酮之方法及異喹啉酮之固體形式
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
EP2914296B2 (en) 2012-11-01 2021-09-29 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
BR112018012255A2 (pt) * 2015-12-18 2018-12-04 Ignyta Inc método para tratar câncer
WO2017180581A1 (en) * 2016-04-15 2017-10-19 Genentech, Inc. Diagnostic and therapeutic methods for cancer
WO2017180817A1 (en) * 2016-04-15 2017-10-19 Musc Foundation For Research Development Treatment of septicemia and ards with erk inhibitors
RU2754507C2 (ru) 2016-06-24 2021-09-02 Инфинити Фармасьютикалз, Инк. Комбинированная терапия
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
WO2019084459A1 (en) * 2017-10-26 2019-05-02 Xynomic Pharmaceuticals, Inc. CRYSTALLINE SALTS AND FORMS OF B-RAF KINASE INHIBITOR
CN112218634A (zh) * 2018-04-09 2021-01-12 G1治疗公司 具有驱动致癌突变的癌症的治疗
CN110656172A (zh) * 2019-01-14 2020-01-07 南方医科大学珠江医院 一种预测小细胞肺癌对ep化疗方案敏感性的分子标志物及试剂盒
US12122787B2 (en) 2019-09-20 2024-10-22 Shanghai Jemincare Pharmaceuticals Co., Ltd Fused pyridone compound, and preparation method therefor and use thereof
CN114981298B (zh) * 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
KR102697384B1 (ko) * 2022-01-13 2024-08-22 팔라디바이오텍 주식회사 리셉터 티로신 키나제 저해제를 탐색하는 방법
CN115177622B (zh) * 2022-07-19 2024-09-17 中南大学湘雅二医院 多个化合物在制备治疗骨髓增殖性肿瘤的药物中的应用
WO2026020045A1 (en) * 2024-07-17 2026-01-22 4M Therapeutics Inc. N-desmethyl ruboxistaurin as a rsk inhibitor for therapeutic use
WO2026030476A1 (en) * 2024-07-30 2026-02-05 Genentech, Inc. Precision medicine for optimal dosage of combined therapies systems and methods of use thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE220114T1 (de) 1993-03-19 2002-07-15 Sequenom Inc Dns-sequenzbestimmung durch massenspektrometrie auf dem weg des abbaus mit exonuklease
US6140053A (en) 1996-11-06 2000-10-31 Sequenom, Inc. DNA sequencing by mass spectrometry via exonuclease degradation
US7439016B1 (en) 2000-06-15 2008-10-21 Digene Corporation Detection of nucleic acids by type-specific hybrid capture method
US7601497B2 (en) 2000-06-15 2009-10-13 Qiagen Gaithersburg, Inc. Detection of nucleic acids by target-specific hybrid capture method
GB0320059D0 (en) 2003-08-27 2003-10-01 Solexa Ltd A method of sequencing
LT3305776T (lt) * 2004-05-14 2020-01-10 Vertex Pharmaceuticals Incorporated Pirolo junginiai kaip erk baltymo kinazės inhibitoriai, ir farmacinės kompozicijos su šiais junginiais
US7582623B2 (en) 2004-05-20 2009-09-01 The Regents Of The University Of California Photoactive metal nitrosyls for blood pressure regulation and cancer therapy
US20060228721A1 (en) 2005-04-12 2006-10-12 Leamon John H Methods for determining sequence variants using ultra-deep sequencing
CA2609387A1 (en) * 2005-05-27 2006-11-30 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
WO2010062546A1 (en) 2008-10-27 2010-06-03 Qiagen Gaithersburg Inc. Fast results hybrid capture assay on an automated platform
KR20120046018A (ko) 2010-10-04 2012-05-09 삼성테크윈 주식회사 단일 뉴클레오티드 다형성의 실시간 ｐｃｒ 검출
WO2012125848A2 (en) 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
EP2953622B1 (en) 2013-02-11 2021-03-24 Abraxis BioScience, LLC Methods of treating melanoma
EP2958592A1 (en) 2013-02-22 2015-12-30 F. Hoffmann-La Roche AG Methods of treating cancer and preventing drug resistance
WO2015095833A1 (en) 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Treatment of hematologic cancers
WO2015095842A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
CA3240745A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatment using combinations of erk and raf inhibitors
WO2015095834A2 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using erk1/2 and bcl-2 family inhibitors
JP6543612B2 (ja) * 2014-03-04 2019-07-10 浩文 山本 大腸癌の治療剤、及び大腸癌患者の予後の予測方法
WO2016025649A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a dot1l inhibitor and related methods
AU2016211246B2 (en) * 2015-01-30 2020-08-27 Biomed Valley Discoveries, Inc. Crystalline forms of C21H22CI2N4O2
JP7180977B2 (ja) * 2015-01-30 2022-11-30 バイオメッド バレー ディスカバリーズ，インコーポレイティド 結晶性Ｃ２１Ｈ２２Ｃｌ２Ｎ４Ｏ２マロン酸塩

Also Published As

Publication number Publication date
MX2022005473A (es) 2022-06-02
IL263108B (en) 2022-08-01
US20220117950A1 (en) 2022-04-21
WO2015095842A3 (en) 2015-08-20
AU2023204587A1 (en) 2023-08-17
US20210038587A1 (en) 2021-02-11
AU2023204587B2 (en) 2025-04-03
US12599593B2 (en) 2026-04-14
EP3458056B1 (en) 2025-10-15
SG11201810287RA (en) 2018-12-28
US10881646B2 (en) 2021-01-05
CL2018003282A1 (es) 2019-10-18
ZA202007734B (en) 2022-04-28
CN109475541A (zh) 2019-03-15
EP4653055A2 (en) 2025-11-26
MX2018014231A (es) 2019-05-15
US20190201387A1 (en) 2019-07-04
MX392121B (es) 2025-03-21
AU2017267804A1 (en) 2019-01-17
EP3458056A4 (en) 2020-01-08
ZA201808480B (en) 2022-04-28
BR112018073786A2 (pt) 2019-02-26
ES3056393T3 (en) 2026-02-20
IL294056A (en) 2022-08-01
IL263108A (en) 2018-12-31
JP2024133638A (ja) 2024-10-02
KR20230025941A (ko) 2023-02-23
US11246859B2 (en) 2022-02-15
CN120501744A (zh) 2025-08-19
CA3024703A1 (en) 2017-11-23
JP2019519519A (ja) 2019-07-11
AU2017267804B2 (en) 2023-04-27
EP3458056A1 (en) 2019-03-27
JP2026053745A (ja) 2026-03-25
JP2022034068A (ja) 2022-03-02
EP4653055A3 (en) 2026-03-18
RU2018145048A (ru) 2020-06-22
AU2025204585A1 (en) 2025-07-10
US20180104228A1 (en) 2018-04-19
US20160317519A1 (en) 2016-11-03
WO2017201532A1 (en) 2017-11-23
WO2015095842A2 (en) 2015-06-25
JP7427212B2 (ja) 2024-02-05

Similar Documents

Publication Publication Date Title
AU2023204587B2 (en) Methods and compositions for treating non-ERK MAPK pathway inhibitor-resistant cancers
RU2722784C2 (ru) Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf
AU2018269982B2 (en) Compositions and methods for treating cancer with atypical BRAF mutations
AU2021203547B2 (en) Human mesothelin chimeric antigen receptors and uses thereof
AU2014368927B2 (en) Cancer treatments using combinations of CDK and ERK inhibitors
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
KR102619197B1 (ko) Hsd17b13 변종 및 이것의 용도
KR20210040948A (ko) 단핵구 및 대식세포의 염증성 표현형을 조절하기 위한 조성물 및 방법, 그리고 이의 면역요법 용도
KR102027394B1 (ko) 탈모 질환의 치료 방법
JP2017528433A (ja) 低い免疫増強用量のｍＴＯＲ阻害剤とＣＡＲの組み合わせ
KR20140147797A (ko) 암 및 자가면역 질환의 치료 방법 및 조성물
CN103097526A (zh) 赋予针对raf和mek抑制剂的抗性的mek1突变
CN111032093A (zh) 控制心肌纤维化和重塑的方法和组合物
KR20160098259A (ko) 인간 메조텔린 키메라 항원 수용체 및 그의 용도
US20210324478A1 (en) Compositions and methods for identification assessment, prevention, and treatment of ewing sarcoma using tp53 dependency biomarkers and modulators
KR20260053547A (ko) 비-erk mapk 경로 억제제-내성 암을 치료하기 위한 방법 및 조성물
HK40006110A (en) Methods and compositions for treating non-erk mapk pathway inhibitor-resistant cancers
RU2812706C2 (ru) Композиции и способы для лечения злокачественной опухоли с атипичными мутациями braf
KR102958345B1 (ko) Hsd17b13 변종 및 이것의 용도
AU2026202687A1 (en) Compositions and methods for modulating monocyte and macrophage inflammatory phenotypes and immunotherapy uses thereof
HK40022785A (en) Compositions and methods for treating cancer with atypical braf mutations
RU2859009C2 (ru) Варианты hsd17b13 и их применения
HK40077678A (en) Human mesothelin chimeric antigen receptors and uses thereof
HK1224332B (en) Human mesothelin chimeric antigen receptors and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181220

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200521

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211122

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20220613

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20211122

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20220613

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20220217

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20200521

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20221011

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220913

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20220613

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20220217

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20211122

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200521

X601 Decision of rejection after re-examination
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20230208

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20221011

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Patent event date: 20220613

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101000287

Request date: 20230208

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101000287; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20230208

Effective date: 20230727

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20230727

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20230208

Decision date: 20230727

Appeal identifier: 2023101000287